News + Blog

Intero Biosystems, a member of Fitzsimons Innovation Community, has been named the winner of Startup Battlefield at TechCrunch Disrupt 2026, earning national recognition for its innovative approach to biotechnology. The achievement highlights Intero’s growing presence in the life sciences industry and brings additional visibility to the innovative companies advancing scientific discovery and commercialization within Colorado’s…

Fitzsimons Innovation Community recently welcomed 47 business, civic and community leaders from Georgia as part of the Greater North Fulton Chamber of Commerce’s 2026 Strategic Leadership Visit to the Denver metropolitan area. The three-day visit provided opportunities for regional leaders to explore approaches to economic development, transportation, redevelopment and innovation. During their visit to Fitzsimons,…

Pathways Bioscience, a member of Fitzsimons Innovation Community, has announced the publication of new clinical research demonstrating that its proprietary botanical formulation, PB125, improved vascular function in older adults and helped preserve vascular function during periods of physical inactivity. The randomized, double-blind, placebo-controlled study, independently conducted by researchers affiliated with the University of Utah, Salt…

The Colorado Child Health Research Institute at Children’s Hospital Colorado has announced its spring 2026 research award recipients, recognizing early-career investigators advancing innovative approaches to pediatric health challenges. Supported in part by philanthropic investment, the awards provide funding for research addressing conditions including traumatic brain injury, chronic lung disease and other complex pediatric health concerns….

The University of Colorado Anschutz has received clearance from the U.S. Food and Drug Administration (FDA) to begin a clinical trial investigating an experimental CAR T-cell therapy for adults with advanced colorectal cancer and pediatric patients with certain solid tumors. Developed by CU Anschutz researchers, the treatment uses genetically modified immune cells designed to target…

Fitzsimons Innovation Community is partnering with Aurora Public Schools and NINE dot ARTS to bring a collaborative public art project to its campus during the 2026-27 school year. The initiative will engage 12th-grade students from the Charles Burrell Visual & Performing Arts Campus in creating a mural that reflects Fitzsimons’ mission, values and connection to…

Cobio Diagnostics, a member of Fitzsimons Innovation Community, has received a $2.2 million Small Business Innovation Research (SBIR) Fast-Track grant from the National Institutes of Health (NIH) to advance its rapid diagnostic technology for urinary tract infections. The funding will support development of a diagnostic test designed to identify infection-causing bacteria directly from patient samples…

CU Anschutz Innovations has announced nine faculty-led projects selected for the 2026 SPARK Colorado and digiSPARK programs, supporting the development and commercialization of emerging medical technologies. The projects span next-generation cell therapies, artificial intelligence, surgical devices, novel diagnostics and treatments for complex diseases. Since launching in 2018, SPARK Colorado has supported 70 projects, helped launch…

Laura White, founder of Andon Bio and a member of Fitzsimons Innovation Community, has been selected for Activate’s 2026 fellowship cohort, joining 50 scientist-innovators working to translate scientific discoveries into commercially viable technologies. Andon Bio is developing a nanopore-based measurement platform designed to improve the predictability of protein production, an essential process in manufacturing biologic…

Jena Hausmann, president and CEO of Children’s Hospital Colorado and a member of the Fitzsimons Innovation Community Board of Directors, has been named to Becker’s Hospital Review’s 2026 list of 236 Women Hospital and Health System Presidents and CEOs to Know. The national recognition highlights Hausmann’s leadership of one of the country’s leading pediatric health…

HepQuant, a member of Fitzsimons Innovation Community, has received premarket approval from the U.S. Food and Drug Administration (FDA) for its SHUNT Liver Diagnostic Test, marking a significant regulatory milestone for the company’s liver disease diagnostic technology. The blood-based test measures liver function and helps clinicians identify certain patients with compensated cirrhosis who are unlikely…

GelSana Therapeutics, a member of Fitzsimons Innovation Community, has announced that two research collaborators, Babita Parajuli and Dr. Amy Wang, received the 2026 Robert B. Lindberg Basic Scientist Paper Award from the American Burn Association for research evaluating GelSana’s CleraFlex wound care technology. The award recognizes research demonstrating that CleraFlex significantly reduced bacterial burden and…